[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632574":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":36,"locations":42,"responsibleParty":65,"collaborators":29,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":29,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":29,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":29,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group T","EXPERIMENTAL","Patients included in this group will receive oral 150 mg theophylline anhydrous tablet (QuibronT\u002FSR, 300 mg dividose tablet, SmithKline Beecham Egypt L.L.C) every 12 hours.",[13],"Drug: Theophylline",{"label":15,"type":10,"description":16,"interventionNames":17},"Group S","Patients included in this group will receive oral 25 mg sumatriptan succinate tablet (Sumigran 25, 25 mg tablet, Sigma pharmaceutical industries, Egypt) every 12 hours.",[18],"Drug: Sumatriptan",{"label":20,"type":10,"description":21,"interventionNames":22},"Group G","Patients included in this group will receive 200 mg of gabapentin every 12 hours.",[23],"Drug: Gabapentin",[25,30,33],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"DRUG","Theophylline",[9],null,{"type":26,"name":31,"description":16,"armGroupLabels":32,"otherNames":29},"Sumatriptan",[15],{"type":26,"name":34,"description":21,"armGroupLabels":35,"otherNames":29},"Gabapentin",[20],[37],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},"Asmaa R Eid, MSc","CONTACT","00201026382543","asmaaragabeid@gmail.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.00192,30.78847,{"lat":54,"lon":53},[57,58,61,63],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},{"name":59,"role":60,"phone":29,"phoneExt":29,"email":29},"Najat S Al Shamaa, MD","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":29,"phoneExt":29,"email":29},"Jihan M Darwish, MD",{"name":64,"role":60,"phone":29,"phoneExt":29,"email":29},"Omnia A El Miseery, MD",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Asmaa Ragab Mohamed","Assistant Lecturer of Anesthesiology, Surgical ICU and Pain Management, Tanta University, Tanta, Egypt.","100632574","theophylline-versus-sumatriptan-and-gabapentin-in-the-treatment-of-post-dural-puncture-headache-100632574",false,"NCT07515456","Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache","A Comparison Between Safety and Efficacy of Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache: A Prospective Randomized Double Blinded Study","Inclusion Criteria:\n\n* Age from 21 to 50 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status ≤ II.\n* Patient's selection for this study will be based on clinical diagnosis suggesting post-dural puncture headache (PDPH) based on the International Headache Society criteria.\n* Patients with numeric rating scale (NRS) of ≥ 5.\n\nExclusion Criteria:\n\n* Pregnant women.\n* History of; chronic headache, cluster headache, migraine, convulsions, cerebrovascular accident, and previous neurological diseases.\n* Signs of meningismus.\n* Dysrhythmia.\n* Hypertension.\n* Ischemic heart disease.\n* Hyperthyroidism.\n* Peripheral vascular disease (ischemic colitis).\n* Liver or renal impairment.\n* Use of selective serotonin reuptake inhibitors.\n* Use of ergotamine derivatives in the past 24 hours.\n* Use of monoamine oxidase inhibitors in the last 2 weeks.\n* Use of any kind of opiates.\n* Allergy to the study medications and any contraindication of oral intake.","ALL","21 Years","50 Years",{"count":80,"type":81},75,"ESTIMATED","INTERVENTIONAL",[84],"NA","The aim of this study is to compare the safety and efficacy of theophylline, sumatriptan, and gabapentin in the treatment of post-dural puncture headache.",[27,31,34,87],"Post-Dural Puncture Headache","2026-03-31",{"date":90,"type":91},"2026-04-07","ACTUAL",{"date":93,"type":91},"2024-12-01",{"date":95,"type":81},"2026-11-01",{"name":5,"class":6},1]